Literature DB >> 12932936

Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk.

Th Roumeguère1, E Wespes, Y Carpentier, P Hoffmann, C C Schulman.   

Abstract

OBJECTIVES: Erectile dysfunction (ED) is frequently of vascular origin. An association between ED and ischemic heart disease has been suggested as a consequence of endothelial disease of penile and coronary arteries. The role of serum lipid levels has been demonstrated in coronary heart disease (CHD), but the relationship with ED is poorly documented. We evaluated undiagnosed hyperlipidemia in ED patients and their coronary heart disease risk.
METHODS: We prospectively compared a group of patients with ED to matched non-ED patients. Risk factors for ED and CHD were noticed and a serum lipid work up (total cholesterol [TC], triglycerides [TG], HDL-cholesterol [HDL-C], LDL-cholesterol [LDL-C] and TC/HDL-C ratio) was measured. We compared the prevalence of hyperlipidemia in the two groups and its impact as predictor of ED. We calculated the risk to develop CHD in patients with or without ED based upon commonly accepted variables of the Framingham Heart study.
RESULTS: 215 patients had ED (mean age 57.6+/-9.6 years) and 100 no ED (mean age 59.7+/-8.3 years). The prevalence of hypercholesterolemia (TC >200 mg/dl or 5.17 mmol/l) was 70.6% vs. 52% in ED and non-ED groups respectively (p=0.06). After exclusion of confounding factors, logistic regression analyses showed HDL-C and TC/HDL-C ratio as significant predictors of ED (p=0.011 and 0.000 respectively). Increased 10-year CHD risk was found in 56.6% in the ED group compared to 32.6% in the control group (p<0.05). The median risk was 12.18% vs. 9.07% respectively with a significant age-related risk (p<001).
CONCLUSIONS: Hyperlipidemia is common in ED patients. HDL-C and TC/HDL-C ratio are predictors of ED. These patients have a high risk of later developing CHD. Erectile dysfunction might therefore serve as sentinel event for coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12932936     DOI: 10.1016/s0302-2838(03)00306-3

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  31 in total

Review 1.  Should patients with erectile dysfunction be evaluated for cardiovascular disease?

Authors:  Kenneth A Ewane; Hao-Cheng Lin; Run Wang
Journal:  Asian J Androl       Date:  2011-11-28       Impact factor: 3.285

2.  Current Diagnosis and Management of Erectile Dysfunction.

Authors:  Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2014-09

3.  Correlation between peak systolic velocity and diameter of cavernosal arteries in flaccid versus dynamic state for the evaluation of erectile dysfunction.

Authors:  R Souper; J Hartmann; M Alvarez; I Fuentes; G Astroza; M Marconi
Journal:  Int J Impot Res       Date:  2017-04-06       Impact factor: 2.896

Review 4.  Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.

Authors:  Ajay Nehra
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

5.  Correlation between penile cavernosal artery blood flow and retinal vascular findings in arteriogenic erectile dysfunction.

Authors:  Ahmed M Emarah; Shawky M El-Haggar; Ihab A Osman; Abdel Wahab S Khafagy
Journal:  Clin Ophthalmol       Date:  2010-09-20

6.  Impaired flow-mediated vasodilatation in Asian Indians with erectile dysfunction.

Authors:  Tanuj Bhatia; Aditya Kapoor; Jatinder Kumar; Archana Sinha; Priyadarshi Ranjan; Sudeep Kumar; Naveen Garg; Satyendra Tewari; Aneesh Srivastava; Rakesh Kapoor; Pravin K Goel
Journal:  Asian J Androl       Date:  2013-05-27       Impact factor: 3.285

7.  Comparison of the differences in circadian autonomic function in hyperlipidemic men with and without erectile dysfunction.

Authors:  M Tolga Dogru; M Murad Basar
Journal:  Int Urol Nephrol       Date:  2009-10-29       Impact factor: 2.370

Review 8.  Metabolic syndrome and risk for ED: a meta-analysis.

Authors:  L H Liu; T Zhang; Y R Zhang; T S Liu; H B Zhang; F Z Chen; S H He; A Y Wei
Journal:  Int J Impot Res       Date:  2014-03-06       Impact factor: 2.896

Review 9.  Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition.

Authors:  A Aversa; M Pili; A Fabbri; E Spera; G Spera
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

Review 10.  Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence.

Authors:  Antonio Martín Morales; Vincenzo Mirone; John Dean; Pierre Costa
Journal:  Clin Interv Aging       Date:  2009-12-29       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.